Compare CDLR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDLR | GHRS |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Denmark | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2023 | 2021 |
| Metric | CDLR | GHRS |
|---|---|---|
| Price | $21.67 | $18.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $42.89 |
| AVG Volume (30 Days) | 72.7K | ★ 299.1K |
| Earning Date | 11-23-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $54.35 | N/A |
| Revenue Next Year | $37.14 | N/A |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.37 | $12.04 |
| 52 Week High | $30.01 | $31.44 |
| Indicator | CDLR | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 22.04 |
| Support Level | $20.96 | $13.58 |
| Resistance Level | $22.21 | $22.88 |
| Average True Range (ATR) | 0.49 | 1.19 |
| MACD | -0.05 | -0.33 |
| Stochastic Oscillator | 47.73 | 2.31 |
Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.